Friday, December 30, 2016 5:45:32 PM
I hope other investments in 2017 treat HDC shareholders better than HDC has treated us over the years. It's hard to fathom that we would be ending the year with the stock price at .013, particularly with Neo having commercialized the prostate test. This doesn't seem plausible, but HDC has proven that it can do anything to disappoint.
Since the company has indicated that it will run out of money by the end of Q1, it should be interesting to see if they quietly turn out the lights, or issue a less-than-credible announcement about suing Neo for not providing HDC with royalties. In any event, since Neo hasn't issued a press release on a test that they invested handsomely in, my guess is that they came to realize the test isn't going to be a game changer after all.
Recent HDVY News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/17/2023 09:13:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/05/2023 07:53:39 PM
FEATURED Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market • Mar 18, 2024 8:51 AM
FEATURED Prospera Energy Inc. Announces a 508% increase in the 2023 Proven Developed Producing (PDP) Reserve Valuation • Mar 18, 2024 8:09 AM
Greenlite Ventures Enters into Strategic Alliance with Woodway USA • GRNL • Mar 15, 2024 4:00 PM
HealthLynked Welcomes David Rosal as New Chief Financial Officer • HLYK • Mar 13, 2024 8:00 AM
ECGI Holdings, Inc. Announces Continued Efforts in Financial Optimization • ECGI • Mar 13, 2024 8:00 AM
PSYC Begins Business Overhaul Process with Consolidation of 10 Previously Issued Convertible Debentures • PSYC • Mar 13, 2024 7:13 AM